Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com
最近 90 天内有 30 个信号。
该公司进入各个市场的顺序 — 从最早到最新
Harbour BioMed任命Patel博士为顾问
Harbour BioMed任命Patel博士为顾问
注册以查看完整信号动态
Harbour BioMed 的国际扩张与竞争对手的对比情况
Harbour BioMed你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Harbour BioMed你 | 3 | 0 | +36% | 26 | 50 |
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
和铂医药任命Adam Zong博士为总裁,负责加强产品管线、推进组合策略及领导合作伙伴关系。Zong拥有超过20年生物制药经验,曾任职默克、百时美施贵宝、辉瑞及恒瑞医药。
和铂医药的HBM9378（针对TSLP的新型抗体）I期试验显示良好安全性和延长半衰期，支持进一步开发用于严重免疫疾病。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Harbour BioMed 的业务、市场和增长信号的快速解答。
